Exendin-4 (Exenatide)
Also known as: Byetta, Bydureon, Exenatide, Exendin-4
Overview
Exendin-4 is a 39-amino acid peptide originally isolated from the venom of the Gila monster lizard (Heloderma suspectum) that shares 53% sequence homology with human GLP-1 but has a much longer half-life of 2.4 hours due to resistance to DPP-4 cleavage at its N-terminus. The synthetic form, exenatide (Byetta/Bydureon), was the first GLP-1 receptor agonist approved by the FDA (2005) for type 2 diabetes management. It demonstrated that pharmacological GLP-1 receptor agonism was a viable therapeutic approach, paving the way for the GLP-1 agonist class that now includes semaglutide and tirzepatide.
Mechanism of Action
Exenatide binds and activates the GLP-1 receptor (GLP-1R), a class B GPCR expressed in pancreatic beta cells, hypothalamic neurons, GI tract, cardiac muscle, and kidneys. GLP-1R activation drives Gs-mediated cAMP production and PKA activation in beta cells, enhancing glucose-dependent insulin secretion while simultaneously suppressing glucagon. Central GLP-1R activation in hypothalamic arcuate and nucleus tractus solitarius neurons promotes satiety and reduces food intake. Gastric emptying is delayed, reducing postprandial glucose excursions. The 39 AA sequence with His1-Gly2 at the N-terminus (vs. His1-Ala2 in GLP-1) confers DPP-4 resistance.
Potential Benefits
- Glucose-dependent insulin secretion (only active when blood glucose is elevated)
- Glucagon suppression reducing hepatic glucose output
- Weight loss (3-5 kg average in clinical trials)
- Cardiovascular risk reduction
- First GLP-1 agonist: established the therapeutic class
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 5 mcg SC 2x daily within 60 min before AM and PM meals |
| Intermediate | 10 mcg SC 2x daily (after 1 month titration) |
| Advanced | 2 mg SC once weekly (Bydureon BCise extended-release) |
| Cycle Duration | Chronic for T2D |
FDA-approved (Byetta 2005, Bydureon 2012). GLP-1 analog derived from Gila monster saliva.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection (pen) ~65-75%
Inject abdomen, thigh, or upper arm. Immediate-release: 60 min before meal. Extended-release (Bydureon BCise): anytime.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Exendin-4 (Exenatide):
T2D Combination Therapy
Standard T2D escalation — exenatide + metformin ± basal insulin.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C. After first use, room temperature up to 30 days (Byetta) or single-use (Bydureon). |
|---|
Bydureon BCise requires 15-second vigorous mixing before injection.
Need exact syringe measurements?
Amino Acid Sequence
His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Side Effects & Safety
- Nausea and vomiting (class effect; most common on initiation)
- Diarrhea
- Rare: pancreatitis (class warning)
- Injection site reactions
- Rare: thyroid C-cell tumors (rodent carcinogenicity data, class warning)
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Personal or Family History of Medullary Thyroid Carcinoma or MEN 2
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Oral Medications (general):
FDA Safety Information
FDA warnings include risk of acute pancreatitis and renal impairment; extended-release form carries a boxed warning for thyroid C-cell tumors.
Pharmacokinetics
| Half-Life | ~2.4 hours (immediate-release); extended-release provides sustained exposure |
|---|---|
| Storage | Refrigerate 2-8°C before first use. After first use: up to 30 days at room temperature (<25°C). Do not freeze. |
Synergistic Compounds
The following compounds have been studied alongside Exendin-4 (Exenatide) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.